Aceclofenac oil drops: characterization and evaluation against ocular inflammation

References

• Abelson MB, Butrus SI, Kliman GH, Larson DL, Corey EJ, Smith LM. 1987. Topical arachidonic acid: a model for screening anti-inflammatory agents. J Ocul Pharmacol. 3:63–74.
   PubMedGoogle Scholar
• Ahuja M, Sharma SK, Majumdar DK. 2007. In vitro corneal permeation of diclofenac from oil drops. Yakugaku Zasshi. 127:1739–1745.
   PubMed Web of Science ®Google Scholar
• Albano B, Anderson RJ, Check JA, Crow W. 2007. Topical glucocorticosteroid formulations. U.S. Patent WO 2007070423 A2.
   Google Scholar
• Avisar R, Robinson A, Appel I, Yassur Y, Weinberger D. 2000. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 19:145–147.
   PubMed Web of Science ®Google Scholar
• Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G. 2003. Systemic linoleic and g-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 22:97–101.
   PubMed Web of Science ®Google Scholar
• Copper LA, Bergamini MV, Leopold IH. 1980. Use of flurbiprofen to inhibit corneal neovascularization. Arch Ophthalmol. 98:1102–1105.
   PubMedGoogle Scholar
• Dogru M, Nakamura M, Shimazaki J, Tsubota K. 2013. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 22:1581–1601.
   PubMed Web of Science ®Google Scholar
• Gonnzález-Alvaro I, Carmona L, Díaz-González F, González-Amaro R, Mollinedo F, Sánchez-Madrid F, Laffón A, García-Vicuña R. 1996. Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheumatol. 23:723–729.
   PubMed Web of Science ®Google Scholar
• Grau M, Montero JL, Guasch J, Felipe A, Carrasco E, Julia S. 1991. The pharmacological profile of aceclofenac, a new non steroidal anti-inflammatory and analgesic drug. Agents Actions Suppl. 32:125–129.
   PubMedGoogle Scholar
• Hecht G, Roehrs RE, Cooper ER, Hiddeman JW, VanDuzee BF. 1990. Evaluation of ophthalmic pharmaceutical products: Modern Pharmaceutics. New York (NY): Marcel Dekker; p. 539–603.
   Google Scholar
• Hersh PS, Rice BA, Baer JC, Wells PA, Lynch SE, Mcguigan LJ, Foster S. 1990. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 108:577–583.
   PubMed Web of Science ®Google Scholar
• Hinz B, Auge D, Rau T, Rietbrock S, Brune K, Werner U. 2003. Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography. Biomed Chromatogr. 17:268–275.
   PubMed Web of Science ®Google Scholar
• Kraff MC, Saunders DR, Mcguigan L, Rannan MG. 1990. Inhibition of blood-aqueous humor barrier breakdown with diclofenac. Arch Ophthalmol. 108:380–383.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. 2003. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 56:307–318.
   PubMed Web of Science ®Google Scholar
• Lemp MA. 2008. Management of dry eye disease. Am J Manag Care. 14:S88–S101.
   PubMed Web of Science ®Google Scholar
• Malhotra M, Majumdar DK. 1997. In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment. Indian J Exp Biol. 35:v1324–v1330.
   PubMedGoogle Scholar
• Maurice DM, Riley MV. 1970. Ocular pharmacokinetics. In: Biochemistry of the eye. London, UK: Academic Press; p. 6–16.
   Google Scholar
• Medzhitov R. 2008. Origin and physiological roles of inflammation. Nature. 454:428–435.
   PubMed Web of Science ®Google Scholar
• Mosteller MW, Gebhardt BM, Hamilton AM, Kaufman HE. 1985. Penetration of topical cyclosporine into the rabbit cornea, aqueous humor, and serum. Arch Ophthalmol. 103:101–102.
   PubMedGoogle Scholar
• Nebbioso M, Fameli V, Gharbiya M, Sacchetti M, Zicari AM, Lambiase A. 2016. Investigational drugs in dry eye disease. Expert Opin Investig Drugs. 25:1437–1446.
   PubMed Web of Science ®Google Scholar
• Neves ML, Yamasaki L, Sanches O, Amaral M, Stevanin H, Giuffrida R, Candido ER, Góes JE, Zulim L, Schweigert A, et al. 2013. Use of linseed oil to treat experimentally induced keratoconjunctivitis sicca in rabbits. J Ophth Inflamm Infect. 3:4.
   PubMedGoogle Scholar
• Ozsoy Y, Gungor S, Cevher E. 2004. Vehicle effects on in vitro release of tiaprofenic acid from different topical formulations. Farmaco. 59:563–566.
   PubMedGoogle Scholar
• Parrilha LR, Nai GA, Giuffrida R, Barbero RC, Padovani LD, Pereira RH, Silva DA, Silva MC, Diniz MS, Andrade SF. 2015. Comparison of 1% cyclosporine eye drops in olive oil and in linseed oil to treat experimentally-induced keratoconjunctivitis sicca in rabbits. Arq Bras Oftalmol. 78:295–299.
   PubMed Web of Science ®Google Scholar
• Pawar PK, Majumdar DK. 2007. In vitro permeation characteristics of moxifloxacin from oil drops through excised goat, sheep, buffalo and rabbit corneas. Pharmazie. 62:853–857.
   PubMed Web of Science ®Google Scholar
• Perry HD, Donnenfeld ED. 2004. Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother. 5:2099–2107.
   PubMed Web of Science ®Google Scholar
• Rashid S, Jin Y, Ecoiff er T, Barabino S, Schaumberg DA, Dana MR. 2008. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 126:210–225.
   Google Scholar
• Roncone M, Bartlett H, Eperjesi F. 2010. Essential fatty acids for dry eye: a review. Cont Lens Anterior Eye. 33:49–54.
   PubMed Web of Science ®Google Scholar
• Rosenfeld SI. 2010. Evaluation and management of post-LASIK dry eye syndrome. Int Ophthalmol Clin. 50:191–199.
   PubMedGoogle Scholar
• Sawazaki R, Ishihara T, Usui S, Hayashi E, Tahara K, Hoshino T, Higuchi A, Nakamura S, Tsubota K, Mizushima T. 2014. Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye. Invest Ophthalmol Vis Sci. 55:2547–2556.
   PubMed Web of Science ®Google Scholar
• Searle AE, Pearce JL, Shaw DE. 1990. Topical use of indomethacin on the day of cataract surgery. Br J Ophthalmol. 74:19–21.
   PubMed Web of Science ®Google Scholar
• Smith SA, Smith SE, Lazare R. 1978. An increased effect of pilocarpine on the pupil by application of the drug in oil. Br J Ophthalmol. 62:314–317.
   PubMed Web of Science ®Google Scholar
• Solomen KD, Cheetham JK, Degryse R, Brint SF, Rosenthal A. 2001. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology. 108:331–337.
   PubMed Web of Science ®Google Scholar
• Sood R. 1999. Medical laboratory technology: methods and interpretations. 4th ed. New Delhi, India: Jaypee Brothers; p. 169–237.
   Google Scholar
• Srinivasan BD, Kulkarni PS. 1980. The role of arachidonic acid metabolites in the mediation of the polymorphonuclear leukocyte response following corneal injury. Invest Ophthalmol Vis Sci. 19:1087–1093.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. 2012. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 130:90–100.
   PubMed Web of Science ®Google Scholar
• Tomlinson A, Louise C, Peter AS. 2013. Effectiveness of dry eye therapy under conditions of environmental stress. Curr Eye Res. 38:229–236.
   PubMed Web of Science ®Google Scholar
• Tran TT, Tran PH, Lee BJ. 2009. Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. Eur J Pharm Biopharm. 72:83–90.
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Kossendrup D, Schulz W, Hoffmann F. 1986. Pharmacokinetic of topical cyclosporin A in the rabbit eye. Invest Ophthalmol Vis Sci. 27:519–524.
   PubMed Web of Science ®Google Scholar